FENNEC PHARMACEUTICALS INC. Form 4 Filing

This filing details a transaction by Jeffrey S. Hackman, Chief Executive Officer and Director of FENNEC PHARMACEUTICALS INC. (FENC), on August 31, 2026. Hackman acquired 1159 common shares under an award granted on March 28, 2025, with the shares released from restriction. The transaction code is "A" for acquisition, and the price per share was $0.0. Following this transaction, Hackman now owns 66,302 shares, categorized as directly held. The filing is made on Form 4, indicating a change in beneficial ownership.